US Health Officials, Tech Executives to Launch Data-Sharing Plan
Health and Human Services Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services Administrator Mehmet Oz are expected to host executives at an event on Wednesday, said the people, who did not provide names of the attendees and asked not to be named because the details haven't been made public.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Woman in Fight with Roommate Over Whether a Home Needs Both a Roomba and a Regular Vacuum
'Most of the time, it just bonks around like a lost toddler at IKEA until someone takes pity on it and turns it around,' the woman saidNEED TO KNOW A woman moved into a shared apartment with two roommates who agreed to share cleaning responsibilities However, she was left unimpressed when one of her roommates began using a Roomba instead of a regular vacuum cleaner 'It doesn't have a hose, can't clean corners or high surfaces, and doesn't work for any kind of mess,' she saidA woman who recently moved into an apartment in Boston with three other PhD students is unsure if she 'overstepped' after buying a vacuum cleaner without discussing it first. On Monday, July 28, the woman explained in a post on Reddit's "Am I The A--hole" forum that she is living with two other women in their mid-twenties, whom she didn't know before moving in. She said they all discussed splitting up the responsibility of keeping the apartment clean prior to the arrangement. However, she was unaware that the vacuum one of her roommates would be bringing was a Roomba. The woman said robot vacuums are ideal for light maintenance if used frequently, but are unsuitable for vacuuming the entire apartment. 'It doesn't have a hose, can't clean corners or high surfaces, and doesn't work for any kind of mess,' she explained. Complaining about her roommate, the woman continued, 'She also only wants to run it every other week, which doesn't really keep up with the dust and dirt of three people. 'The Roomba also hasn't mapped the apartment well due to its infrequent use,' she said. 'Most of the time, it just bonks around like a lost toddler at IKEA until someone takes pity on it and turns it around.' The woman said that when she tried to discuss her concerns with her roommate, the Roomba owner disagreed on the need to have a separate regular vacuum cleaner. In an attempt to avoid an argument, the woman said she bought her own regular vacuum that had a bag and an allergy filter to use in her bedroom and shared areas. 'When I brought it home, she was annoyed and said I had gone behind her back and broken our agreement,' the woman said of her roommate. 'I didn't see it that way, and shared that I'm not asking anyone else to use it or share costs. I just wanted to be able to clean the apartment to a level that works for me." 'Our other roommate said she doesn't really have a preference and doesn't care, so it seems like she is currently steering clear of this,' she continued. 'There's no blame or fault to be found in her at all; I totally understand why she might want to stay neutral." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. 'I don't want to be the problem roommate, but now I'm wondering if I overstepped. AITA [am I the a--hole?],' the woman asked. Responses to the post reassured the woman that her views on the Roomba were fair. One person said her roommate was 'acting like a child,' while another argued there should be no issue with the addition of the vacuum because the Roomba can still be used. 'This is absurd. You are allowed to buy whatever you want for your shared apartment. Roommate sounds like a problem now and future,' someone else chimed in. Read the original article on People Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Blue Origin's Latest Launch Sends Crypto Billionaire Justin Sun to Space After He Bid $28M for Seat on 10-Minute Flight
"When I look at it from space, Earth is so small and that's our home," Sun said after his brief trip on the New Shepard rocketNEED TO KNOW Blue Origin, founded by Jeff Bezos, brought another crew to space The crew included cryptocurrency billionaire Justin Sun, who bid $28 million for the seat on the rocket, along with five others The mission was the 34th flight for the New Shepard programSix more people have gone to space thanks to Blue Origin. The space technology company, founded by Jeff Bezos, brought another crew to space on Sunday, August, 3, including cryptocurrency billionaire Justin Sun. The mission — known as NS-34 —was the 34th flight for the New Shepard program, according to the Blue Origin website. The crew launched from West Texas on the New Shepard rocket at 8:43 a.m. local time, per Blue Origin's X. Another post confirmed that the flight controllers "confirmed capsule separation" about three minutes later, which means the crew experienced "weightlessness." "Crew Capsule apogee confirmed," Blue Origin wrote at 8:47 a.m., before confirming that the crew had "landed" mere minutes later. Another update stated that the aircraft reached touchdown at 8:53 a.m., after a total of 10 minutes. "Welcome back, NS-34 crew," the company wrote on social media. Blue Origin reported that the company "successfully completed its 14th human spaceflight" following the flight. Along with Sun, the crew included real estate investor Arvi Bahal, Turkish businessman Gökhan Erdem, meteorologist Deborah Martorell, educator Lionel Pitchford and entrepreneur J.D. Russell. Sun won a bid for his seat on the New Shepard in 2021. He bid $28 million for the seat, according to Bloomberg and The outlet reported that he was supposed to be on the landmark flight on July 20, 2021, in recognition of the 52nd anniversary of the Apollo 11 moon landing, but was unable to make the trip due to a scheduling conflict. "It was an honor to see so many nations represented on our flight today. The view of our fragile planet from space has a unifying effect on all who witness it, and I am always eager to see how our astronauts use this experience for the benefit of Earth," said Phil Joyce, Senior Vice President of Blue Origin, in a statement. Per Blue Origin's website, the New Shepard is a "fully reusable, suborbital rocket system built for human flight from the beginning." During the autonomous aircraft's 11-minute trip, those onboard pass the Kármán line into space. The crew experiences "several minutes of weightlessness and witnessing life-changing views of Earth." Singer Katy Perry, broadcast journalist Gayle King, philanthropist Lauren Sánchez, former NASA rocket scientist Aisha Bowe, bioastronautics research scientist Amanda Nguyen and film producer Kerianne Flynn notably went to space on the New Shepard in April as part of its 31st launch. Sun reflected on his brief journey into space in an interview shared on his Instagram. "For this mission, I've waited for four years but we've finally delivered it. I really appreciate Mr. Bezos and his team for making this possible. And thank you dad and mom for bringing me to Earth," he said. "When I look at it from space, Earth is so small and that's our home. We definitely need to do whatever we can do to protect it," Sun added. The entrepreneur made headlines in November 2025 for buying viral artwork depicting a yellow banana duct-taped to a wall. 'This is not just an artwork; it represents a cultural phenomenon that bridges the worlds of art, memes and the cryptocurrency community,' Sun wrote on X. 'I believe this piece will inspire more thought and discussion in the future and will become a part of history.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. "I am honored to be the proud owner of the banana 🍌 and look forward to it sparking further inspiration and impact for art enthusiasts around the world," Sun continued. He later consumed the banana used in the artwork, writing in another X post, "To be honest, for a banana with such a back story, the taste is naturally different from an ordinary one. I could discern a hint of what Big Mike bananas from 100 years ago might have tasted like." Read the original article on People Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
